Adjuvant therapy of primary breast cancer. Closing summary and outlook.

Adjuvant therapy of primary breast cancer. Closing summary and outlook. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Adjuvant therapy of primary breast cancer. Closing summary and outlook. Abstract Text:

J H Glick,

Adjuvant therapy of primary breast cancer. Closing summary and outlook. Publishing Authors By Initials

JH Glick,

For similar organic chemicals: hydrocarbons: hydrocarbons, cyclic: hydrocarbons, aromatic: benzene derivatives: benzylidene compounds: stilbenes: tamoxifen research abstracts see: organic chemicals: hydrocarbons: hydrocarbons, cyclic: hydrocarbons, aromatic: benzene derivatives: benzylidene compounds: stilbenes: tamoxifen research

PUBMED ID PMID:

MEDLINE DATE:

Adjuvant therapy of primary breast cancer. Closing summary and outlook. Journal Published:

PUBLICATION TYPE: Review

Journal: Recent results in cancer research. Fortschritte de

VOLUME: 115

Page Numbers: 283-92

Journal Abbreviation: Recent Results Cancer Res.

ISSN: 0080-0015

DAY: 13

MONTH: 02

YEAR: 1989

Adjuvant therapy of primary breast cancer. Closing summary and outlook. Information

Number of References: 2

LANGUAGE: eng

NlmUniqueID: 44671

Adjuvant therapy of primary breast cancer. Closing summary and outlook. Keywords Mesh Terms:

KEYWORDS: Tamoxifen

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: Adjuvant therapy of primary breast cancer. Closing summary and outlook. Information

Substance Name: Tamoxifen

Registry Number: 10540-29-1

Grant and Affiliation Information for Adjuvant therapy of primary breast cancer. Closing summary and outlook.

AFFILIATION: Cancer Center, University of Pennsylvania, Philadelphia 19104.

Country: GERMANY, WEST

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Recent Results Cancer Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Adjuvant therapy of primary breast cancer Closing summary and outlook Related Publications

• 1-Aminocyclopropane-1-carboxylate deaminase from Pseudomonas putida UW4 facilitates the growth of canola in the presence of salt.
• Adjuvant therapy of primary breast cancer. Closing summary and outlook.
• Breast CT.
• Causation: a loosely founded concept in epidemiology.
• Clinical trials and external validity.
• Closing in on the Puzzle of ONJ.
• Comorbidities in older patients with HIV: a retrospective study.
• Double-contrast barium enema for colorectal cancer screening: a review of the issues and a comparison with other screening alternatives.
• Effect of somatic mutation on DNA binding properties of anti-DNA autoantibodies.
• Ethical considerations in publishing research involving human subjects.
• Expression profile of skin papillomas with high cancer risk displays a unique genetic signature that clusters with squamous cell carcinomas and predicts risk for malignant conversion.
• Flexible 3D pharmacophores as descriptors of dynamic biological space.
• Fluorescence microscopy and thin-section electron microscopy.
• Focus your leadership. Preparing for a major incident response.
• Immigration and living arrangements: moving beyond economic need versus acculturation.
• Inhibition of the mitochondrial F1F0-ATPase by ligands of the peripheral benzodiazepine receptor.
• Marañón, intersexuality and the biological construction of gender in 1920s Spain.
• Measles outbreak in a Vancouver school population: relative risk and vaccine efficacy.
• Mechanistic basis for therapeutic targeting of the mitochondrial F1F0-ATPase.
• Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study.
• Mucolytic enzyme systems; effects of tissue extracts and body fluids, certain steroids, and hemoglobin derivatives on hyaluronidase activity.
• Mucolytic enzyme systems; inhibition of hyaluronidase by human blood serum during the normal menstrual cycle and pregnancy.
• Mucolytic enzyme systems; inhibition of hyaluronidase by serum in human cancer.
• Mucolytic enzyme systems; inhibition of hyaluronidase by serum in infectious diseases.
• Oncology in transition: the pivotal role of the American Society of Clinical Oncology.
• Poverty and human development: a challenge for us all.
• Risky liaisons: what is the relationship between oral conditions and nonoral diseases?
• Role of conformational dynamics in sequence-specific autoantibody*ssDNA recognition.
• Smooth handoffs. How to put the team focus back into ALS/BLS interactions.
• Structural modeling of sequence specificity by an autoantibody against single-stranded DNA.